Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) may arise from genomic instability and has dismal outcome. Sorafenib is the first-line treatment for advanced stage HCC, but its therapeutic efficacy is less than 50%. Biomarkers for predicting the therapeutic efficacy of sorafenib administration to patients with advanced HCC are required. Here, we evaluated the role of chromosomal copy number aberrations (CNAs) in patients with advanced HCC who were treated with sorafenib along with their drug response.

Methods

The response to sorafenib treatment of twenty-three HCC patients who developed advanced recurrence after partial hepatectomy was analyzed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Formalin fixed paraffin embedded (FFPE) tissue specimens obtain

SUBMITTER: Yu MC 

PROVIDER: S-EPMC9038951 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature